PFE · News · 20261030N

Regulatory Approval Milestones

PFIZER INC · 2026-10-30 · Importance 41 · Surprise 60

The FDA expanded approval of Pfizer’s TALZENNA plus XTANDI for men with metastatic hormone-sensitive prostate cancer with homologous recombination repair gene mutations. The digest does not provide an approval date, market size, or quantified financial impact.

Key facts